Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060487 · ClinicalTrials.gov registry record · Phase 4
Effects of Oral Sildenafil on Mortality in Adults With PAH
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 4
- Development phase
- 385
- Enrollment target
NCT02060487 is a Phase 4 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 385 participants.
The verdict
NCT02060487, a Phase 4 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 385 participants
- Enrollment target
Study Summary
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day \[TID\]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) will be assessed.
Interventions
- DRUG sildenafil citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2014-09-22 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02060487
The ClinicalTrials.gov registry entry for NCT02060487 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sildenafil citrate is the first listed.
NCT02060487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02060487 about?
NCT02060487 is a clinical study titled "Effects of Oral Sildenafil on Mortality in Adults With PAH". This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day \[TID\]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) wil...
What is the current status of trial NCT02060487?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 385 participants. The study started on 2014-09-22. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT02060487?
The interventions under investigation include: sildenafil citrate (DRUG).
Who is sponsoring clinical trial NCT02060487?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.